SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco's stock is trending amidst discussions about its recent earnings report, with debates focusing on whether the results justify its high valuation and P/E ratio. Some investors are concerned about potential tariff impacts, while others highlight the company's strong membership model and consistent sales. Community sentiment appears divided between bulls citing Costco's resilience and bears pointing to limited growth and technical indicators.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its commitment to building and delivering value, despite recent market dips. With new exchange listings, upcoming utilities, and a buy contest, the community emphasizes its active development team and transparency. Many express excitement about the potential for a strong recovery and a future meetup.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending amid speculation around a potential TikTok deal and its impact on user migration. The community is buzzing about buyout rumors, high trading volume, and potential partnerships, while also considering SNAP's position relative to TikTok and other social media platforms. Some believe a shift in TikTok's user base could benefit SNAP, especially if its algorithm changes.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as the community discusses a recent shelf registration for a potential $300M offering, drawing comparisons to a similar situation with $DEFT and sparking concerns about possible dilution after a Nasdaq uplisting. While some view this as a necessary step for growth and expansion, others worry about the timing and potential impact on the stock price, despite the CEO's significant stake in the company.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending after announcing FDA approval of PALSONIFY for acromegaly treatment, leading to widespread congratulations among investors. The community is actively discussing the drug's potential market value, revenue estimates, and potential impact on patients currently burdened by injections. Anticipation is building for a conference call where further details may be revealed, with some expecting significant premarket movement.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending due to ongoing discussions about government support for critical mineral companies and the potential impact of geopolitical events on rare earth supply chains. The community is analyzing MP's strategic position as a U.S. rare earth producer, especially compared to peers, and anticipating upcoming catalysts like the commencement of a price floor agreement. Some traders are also discussing technical indicators and potential price targets, while others debate the stock's valuation.

N2OFF, Inc. is a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech. It delivers integrated solutions for sustainable energy, greenhouse gas emissions reduction and safety, quality solutions for the agri- tech market. Its products include SpuDefender and FreshProtect. The SpuDefender is designed to control the post-harvest potato sprout. The FreshProtect is designed to control spoilage-creating microorganisms on post-harvest citrus fruit. The firm operates through the following segments: Pathogen prevention and prolong shelf life and N2O emissions Global warming solutions. N2OFF was founded by Nimrod Ben-Yehuda on April 1, 2009 and is headquartered in Neve Yarak, Israel.

N2OFF Inc.

N2OFF ($NITO) is trending due to discussions around a recent spike and subsequent volatility, with some traders pointing to dilution concerns and others eyeing dip-buying opportunities. The community is debating whether the stock is a pump-and-dump scheme or a potential swing trade, with merger news and a low float adding to the speculation. Some traders mention a reverse stock split and potential effects of that event.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining ($CIFR) is trending due to a recently announced AI hosting agreement with Fluidstack, backed by Google, which includes a significant financial guarantee and equity stake. While the news initially spurred excitement, the company's concurrent announcement of a convertible note offering has led to community concerns about potential dilution and a sell-off, despite the long-term growth prospects in the AI data center space. The community is actively debating the impact of the offering versus the potential benefits of the Google-backed deal, with some viewing the dip as a buying opportunity.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

PUPU.X is trending as community members discuss bullish momentum and potential breakouts. Some users are pointing to positive chart signals and increased buying pressure. The conversation includes references to other cryptos like BTC.X and SOL.X.

RYIU Token is the native digital currency for RYI Unity with premiere token features designed to enhance users experience

RYI Unity LLC

RYIU.X is trending as the community rallies to increase visibility and trading volume, expressing excitement about its potential. Some investors are drawn to RYIU.X as an alternative during a downturn in the broader crypto market, while others are seeking more information and insight on the coin's fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy

Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.

Arrowhead Pharmaceuticals, Inc. (ARWR) on Tuesday announced a global licensing and collaboration agreement with Swiss pharmaceutical giant Novartis (NVS) for its investigational therapy for the treatment of neurodegenerative disorders such as Parkinson’s Disease.Under the agreement, Novartis will receive an exclusive worldwide license to research, develop, manufacture, and commercialize ARO-SNCA, a preclinical-stage program for the potential treatment of patients with Parkinson’s disease and other synucleinopathies. Novartis will also select additional collaboration targets outside of Arrowhead’s current pipeline to be developed using Arrowhead’s Targeted RNAi Molecule (TRiM) platform, Arrowhead said.Meanwhile, Arrowhead will <a target="_blank" rel="noopener noreferrer nofollow" href="https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-and-novartis-enter-into-a-global-license-and-collaboration-agreement/">receive</a> a $200 million upfront payment and is eligible to receive up to $2 billion in potential milestone payments, in addition to royalties on commercial sales.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> rose by 11% at the time of writing, while NVS stock traded marginally in the red. On Stocktwits, retail sentiment around ARWR stayed within ‘bearish’ territory over the past 24 hours, while message volume rose to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_9_57_14_AM_png_dadf30ac72.webp" alt="ARWR's Sentiment Meter and Message Volume as of 9:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>ARWR's Sentiment Meter and Message Volume as of 9:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:574/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_10_00_31_AM_png_703e9e6f44.webp" alt="NVS's Sentiment Meter and Message Volume as of 10:00 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="574" height="60"><figcaption>NVS's Sentiment Meter and Message Volume as of 10:00 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes that Arrowhead getting $200 million upfront for a pre-clinical asset is a “hell of a deal.”<stembedurl>https://stocktwits.com/Pika_Capital/message/627215281</stembedurl>Arrowhead will conduct and complete the necessary preclinical research activities to enable the filing of a clinical trial application for all licensed programs under the agreement. Novartis will then assume sole control over development, manufacturing, medical affairs, and commercialization activities. The transaction is expected to close in the second half of 2025.CEO Christopher Anzalone stated that the company looks forward to beginning clinical trials for ARO-SNCA “as soon as possible.” Both ARWR stock and NVS stock is up by about 30% this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-stock-tanks-after-cancer-drug-candidate-update/chv6sI8Rdny">Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’

Under the agreement, Arrowhead will receive a $200 million upfront payment and is eligible to receive up to $2 billion in potential milestone payments, as well as royalties on commercial sales.

Equity

H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its credibility in capital allocation.The firm also highlighted concerns that Sarepta's late-stage and commercial portfolio may not generate sufficient near-term cash to support its current debt and pipeline ambitions.H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. The brokerage noted that <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> fully unwound its equity position in Arrowhead less than a year after investing $325 million in the stock. The unwinding represented a 31% decline as compared to the purchase price, it added.On Stocktwits, retail sentiment around the stock trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Retail chatter around the stock jumped 131% over the past 24 hours, as of Thursday morning.<figure class="image"><img style="aspect-ratio:625/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_11_12_15_AM_png_aaca6c7ce4.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="625" height="58"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Sarepta selling its investment in Arrowhead.<stembedurl>https://stocktwits.com/Zergg/message/625149352</stembedurl>Another user hopes the stock will hit $30 by next week.<stembedurl>https://stocktwits.com/markxtill/message/625143002</stembedurl>Sarepta on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-keeps-retail-traders-bullish-as-stock-surges-on-100-m-milestone-payment-to-arrowhead-in-genetic-disorder-trial/chsR9ZARdak">said</a> that it sold about 9.27 million shares of common stock of Arrowhead in a privately negotiated block trade from which it expects to receive at least $174 million in gross proceeds.The company also said that it has entered into an agreement with Arrowhead under which it will transfer over 2.66 million shares of <a href="https://stocktwits.com/symbol/ARWR">Arrowhead</a> back to the company to satisfy a $50 commitment of a $100 milestone payment obligation. The remaining $50 million will be received in cash, Arrowhead said. Sarepta previously owned 11.93 million shares of Arrowhead stock.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure. Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.However, SRPT stock is down by 84% this year and by 85% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hertz-expands-program-allowing-prolonged-3-day-test-drives-before-vehicle-purchase-to-over-100-cities/chsRlcNRdOh">Hertz Expands Program Allowing Prolonged 3-Day Test Drives Before Vehicle Purchase To Over 100 Cities</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Sarepta Sells Arrowhead Stake to Fund Milestone Payment

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Shares of Sarepta Therapeutics hit their highest level in nearly a month on Wednesday after the company said a safety review and enrollment progress in its Phase 1/2 trial of SRP-1003 for type 1 myotonic dystrophy (DM1) triggered a $100 million milestone payment to Arrowhead Pharmaceuticals.<a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> jumped 8.5% to close at $20.4 on Wednesday, with an additional 1.6% gain in after-hours trading.The payment was triggered after Arrowhead reached the first of two predetermined enrollment targets in the study, following a review of the safety data.&nbsp;SRP-1003 is an experimental RNA interference therapy being developed for type 1 myotonic dystrophy.To help fund the milestone payment, Sarepta sold 9.3 million shares of Arrowhead in a privately negotiated block trade, generating at least $174 million in gross proceeds.&nbsp;Arrowhead will also redeem 2.7 million shares from Sarepta for $50 million, prefunding half of the milestone obligation.The company plans to share early results from the SRP-1003 trial and its facioscapulohumeral muscular dystrophy (FSHD) program in the second half of 2025.On Stocktwits, retail sentiment was ‘bullish’ for Sarepta Therapeutics and ‘extremely bullish’ for Arrowhead Pharmaceuticals, with 24-hour message volumes surging 872% and 122%, respectively.One user remarked that upgrades for Sarepta Therapeutics keep coming, adding that the market may be underestimating how quickly sentiment can shift when major investors get involved.&nbsp;<stembedurl>https://stocktwits.com/BookerB/message/625098239</stembedurl>Another said the stock could still rise tenfold within a year if European approval comes through and with multiple trials underway, calling it a bargain and urging others to buy before the current discount disappears.<stembedurl>https://stocktwits.com/Mejeko/message/625096804</stembedurl>While Sarepta’s stock has declined 83.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/ARWR">Arrowhead’s stock</a> gained 6.3% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

Sarepta to Report Q2 Earnings: What's in Store for the Stock?

SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

Arrowhead Pharmaceuticals, Inc. (ARWR) announced on Wednesday that it expects its licensing partner, Sarepta Therapeutics (SRPT), to continue meeting its required financial obligations to the company despite recent setbacks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARWR">Arrowhead</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_11_32_10_AM_png_db10f4a9a5.webp" alt="ARWR's Sentiment Meter and Message Volume as of 11:30 a.m. ET on July 23, 2025 | Source: Stocktwits" width="624" height="61"><figcaption>ARWR's Sentiment Meter and Message Volume as of 11:30 a.m. ET on July 23, 2025 | Source: Stocktwits</figcaption></figure>Retail chatter around Arrowhead increased by 83% over the past seven days.Arrowhead has an ongoing exclusive license and collaboration agreement with <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a>, including four clinical-stage drug candidates and three pre-clinical programs.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250723517597/en/Arrowhead-Pharmaceuticals-Issues-Statement-on-the-Status-of-its-Ongoing-Agreement-with-Sarepta-Therapeutics">stated</a> on Wednesday that it continues to conduct clinical and non-clinical studies as stipulated in the agreement and that Sarepta has provided no indication of any intention to fail to fulfill its obligations. Furthermore, Sarepta has experienced setbacks in products and programs unrelated to those licensed from Arrowhead, the company noted.However, if Sarepta fails to meet its financial obligations, there are clear termination provisions that would cause assets and associated intellectual property to be returned to Arrowhead, the company stated. Arrowhead would further have no obligation to return any consideration Sarepta had already paid, it noted.Upon closing the agreement with Sarepta in February, Arrowhead received a $500 million upfront payment and an additional $325 million through Sarepta's purchase of Arrowhead common stock. As per the terms of the agreement, Arrowhead will also receive $250 million, payable in annual installments of $50 million over five years, and is eligible to receive $300 million in near-term payments associated with certain milestones.Arrowhead believes it is on track to earn the first $100 million soon and the remaining $200 million by year-end.A Stocktwits user applauded the “tone and positioning” of Arrowhead’s announcement.<stembedurl>https://stocktwits.com/johnnygogogo/message/622060994</stembedurl>Earlier this week, Sarepta <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-pauses-elevidys-shipments-amid-fda-label-review/ch8MbFbR5rD">announced a voluntary halt</a> to U.S. shipments of its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.On Stocktwits, retail sentiment around Sarepta trended in the ‘extremely bullish’ territory, coupled with ‘extremely high’ message volume. The message count around Sarepta has surged 595% over the past seven days.<figure class="image"><img style="aspect-ratio:626/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_11_30_36_AM_png_2a121005a7.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:30 a.m. ET on July 23, 2025 | Source: Stocktwits" width="626" height="60"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:30 a.m. ET on July 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for Sarepta’s Elevidys to be reintroduced to the market.<stembedurl>https://stocktwits.com/Newcar/message/622087250</stembedurl>At the time of writing, ARWR stock was trading 11% higher, while SRPT stock had risen by 2%.SRPT stock, however, has fallen by about 89% this year.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-collaborates-with-four-critical-mineral-producers-to-strengthen-supply-chain/ch8wsttR5MC">Lucid Collaborates With 4 Critical Mineral Producers To Strengthen Supply Chain: Retail Deems It A ‘Comeback’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement

Arrowhead believes it is on track to earn the first $100 million soon and the remaining $200 million by the end of the year under its agreement with Sarepta. 

SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots

Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARWR News

ARWR Arrowhead Pharmaceuticals Inc.